Evidence for pleiotropic effects of statins in clinical trials

Ping Yen Liu, Chao Yung Wang, James K. Liao

Research output: Contribution to journalArticle

Abstract

Lipid-lowering agents, such as 3-hydroxy-3-methylglutaryl coenzyme A(HMG CoA) Teductase inhibitors, also known as statins, have been shown to reduce cardiovascular events. However, evidence from recent clinical trials suggests that the beneficial effects of statins may be derived from both lipid lowering and non-lipid lowering, or "pleiotropic" effects. Animal studies suggest that some of these pleiotropic effects of statins are mediated by inhibition of Rho kinase (ROCK). ROCK has been shown important in regulation of vascular tone, cell proliferation, inflammation and oxidative stress. In the cardiovascular system RhoA/ROCK pathway has also been implicated in angiogenesis, atherosclerosis, cerebral and coronary vasospasm, cerebral ischemia, hypertension, myocardial hypertrophy, and neointima formation after vascular injury. Indeed, in clinical studies, elevated ROCK activity is associated with cardiovascular risks and inhibition of ROCK leads to improved endothelial function. Therefore, modulation of the RhoA/ROCK pathway by statins may provide additional benefits beyond their lipid lowering effects, especially among high-risk cardiovascular patients.

Original languageEnglish
Pages (from-to)116-121
Number of pages6
JournalImmunology, Endocrine and Metabolic Agents in Medicinal Chemistry
Volume8
Issue number2
DOIs
Publication statusPublished - 2008 Jun 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Clinical Trials
Lipids
Coronary Vasospasm
Intracranial Vasospasm
Neointima
rho-Associated Kinases
Vascular System Injuries
Cardiovascular System
Brain Ischemia
Hypertrophy
Blood Vessels
Atherosclerosis
Oxidative Stress
Cell Proliferation
Hypertension
Inflammation

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Pharmacology

Cite this

@article{02a3867f408047c6a15f31f879de843d,
title = "Evidence for pleiotropic effects of statins in clinical trials",
abstract = "Lipid-lowering agents, such as 3-hydroxy-3-methylglutaryl coenzyme A(HMG CoA) Teductase inhibitors, also known as statins, have been shown to reduce cardiovascular events. However, evidence from recent clinical trials suggests that the beneficial effects of statins may be derived from both lipid lowering and non-lipid lowering, or {"}pleiotropic{"} effects. Animal studies suggest that some of these pleiotropic effects of statins are mediated by inhibition of Rho kinase (ROCK). ROCK has been shown important in regulation of vascular tone, cell proliferation, inflammation and oxidative stress. In the cardiovascular system RhoA/ROCK pathway has also been implicated in angiogenesis, atherosclerosis, cerebral and coronary vasospasm, cerebral ischemia, hypertension, myocardial hypertrophy, and neointima formation after vascular injury. Indeed, in clinical studies, elevated ROCK activity is associated with cardiovascular risks and inhibition of ROCK leads to improved endothelial function. Therefore, modulation of the RhoA/ROCK pathway by statins may provide additional benefits beyond their lipid lowering effects, especially among high-risk cardiovascular patients.",
author = "Liu, {Ping Yen} and Wang, {Chao Yung} and Liao, {James K.}",
year = "2008",
month = "6",
day = "1",
doi = "10.2174/187152208784587890",
language = "English",
volume = "8",
pages = "116--121",
journal = "Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry",
issn = "1871-5222",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

Evidence for pleiotropic effects of statins in clinical trials. / Liu, Ping Yen; Wang, Chao Yung; Liao, James K.

In: Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, Vol. 8, No. 2, 01.06.2008, p. 116-121.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evidence for pleiotropic effects of statins in clinical trials

AU - Liu, Ping Yen

AU - Wang, Chao Yung

AU - Liao, James K.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Lipid-lowering agents, such as 3-hydroxy-3-methylglutaryl coenzyme A(HMG CoA) Teductase inhibitors, also known as statins, have been shown to reduce cardiovascular events. However, evidence from recent clinical trials suggests that the beneficial effects of statins may be derived from both lipid lowering and non-lipid lowering, or "pleiotropic" effects. Animal studies suggest that some of these pleiotropic effects of statins are mediated by inhibition of Rho kinase (ROCK). ROCK has been shown important in regulation of vascular tone, cell proliferation, inflammation and oxidative stress. In the cardiovascular system RhoA/ROCK pathway has also been implicated in angiogenesis, atherosclerosis, cerebral and coronary vasospasm, cerebral ischemia, hypertension, myocardial hypertrophy, and neointima formation after vascular injury. Indeed, in clinical studies, elevated ROCK activity is associated with cardiovascular risks and inhibition of ROCK leads to improved endothelial function. Therefore, modulation of the RhoA/ROCK pathway by statins may provide additional benefits beyond their lipid lowering effects, especially among high-risk cardiovascular patients.

AB - Lipid-lowering agents, such as 3-hydroxy-3-methylglutaryl coenzyme A(HMG CoA) Teductase inhibitors, also known as statins, have been shown to reduce cardiovascular events. However, evidence from recent clinical trials suggests that the beneficial effects of statins may be derived from both lipid lowering and non-lipid lowering, or "pleiotropic" effects. Animal studies suggest that some of these pleiotropic effects of statins are mediated by inhibition of Rho kinase (ROCK). ROCK has been shown important in regulation of vascular tone, cell proliferation, inflammation and oxidative stress. In the cardiovascular system RhoA/ROCK pathway has also been implicated in angiogenesis, atherosclerosis, cerebral and coronary vasospasm, cerebral ischemia, hypertension, myocardial hypertrophy, and neointima formation after vascular injury. Indeed, in clinical studies, elevated ROCK activity is associated with cardiovascular risks and inhibition of ROCK leads to improved endothelial function. Therefore, modulation of the RhoA/ROCK pathway by statins may provide additional benefits beyond their lipid lowering effects, especially among high-risk cardiovascular patients.

UR - http://www.scopus.com/inward/record.url?scp=46649106311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46649106311&partnerID=8YFLogxK

U2 - 10.2174/187152208784587890

DO - 10.2174/187152208784587890

M3 - Article

AN - SCOPUS:46649106311

VL - 8

SP - 116

EP - 121

JO - Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

JF - Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

SN - 1871-5222

IS - 2

ER -